HUYABIO International

86 articles about HUYABIO International

• HUYA Bioscience International Announces Orphan Drug Designation for HBI-8000 Monotherapy Adult T-cell Leukemia-Lymphoma ATL in Japan

  9/28/2020

  HUYA Bioscience International (HUYABIOTM), the leader in accelerating global development of China's pharmaceutical innovations, announced today the Ministry of Health, Labour and Welfare (MHLW) granted HBI-8000 orphan drug designation (ODD) in Japan as monotherapy for relapsed or refractory Adult T-cell Leukemia-Lymphoma or (ATL).

• HUYA Bioscience International Licenses the Novel SHP2 Inhibitor HBI-2376 for Development in Oncology

  8/4/2020

   HUYA Bioscience International (HUYABIO ® ), the leader in accelerating global development of China's pharmaceutical innovations, announced today it has exclusively licensed worldwide rights, outside of China , to the SHP2 inhibitor, HBI-2376, from Suzhou GenHouse. SHP2 is an import

• HUYA Bioscience International® Announces the Successful Completion of Phase 1 Trial of HBI-3000

  2/28/2020

  HUYA Bioscience International, the leader in accelerating global development of China's pharmaceutical innovations, has presented the results of a Phase I study of HBI-3000, a novel drug for cardioversion of atrial fibrillation (AF).

• HUYA Bioscience International Appoints Meiji Seika Pharma as Exclusive Distributor For HBI-8000 in Japan and Other Asian Countries

  1/8/2020

  HUYA Bioscience International CEO & Executive Chair, Dr. Mireille Gillings announced the appointment of Meiji Seika Pharma as an exclusive distributor for its lymphoma product, HBI-8000, in Japan.

• HUYA Bioscience International expanded oncology pipeline includes combination with checkpoint inhibitor for solid tumors

  6/4/2018

  HUYA Bioscience International (HUYA) announced it is at a key stage in the company's development of HBI-8000, HUYA's lead novel epigenetic drug with important immunomodulatory properties.

• HUYA Bioscience Establishes Strategic Partnership With Suzhou BioTOP

  7/10/2017

• HUYA Bioscience Release: Biopharma And CAS Innovation And Investment Company Establish Strategic Collaboration

  1/18/2017

• HUYA Bioscience's Dr. Mireille Gillings Named Pharma Executive Of The Year At The Biopharma Industry Awards 2016

  3/24/2016

• HUYA Bioscience Adds To Executive Team

  3/23/2016

• HUYA Bioscience Celebrates 10 Years In China

  3/22/2016

• HUYA Bioscience Acquires Exclusive Rights To Immuno-Oncology Products From Fudan University

  3/15/2016

• HUYA Bioscience Expands Senior Management Team

  3/3/2016

• Eisai Company Buys Cancer Drug Rights From HUYA Bioscience in $280 Million+ Deal

  2/1/2016

• HUYA Bioscience International Adds To Senior Management Team

  12/23/2015

• HUYA Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan

  12/22/2015

• HUYA Bioscience International Expands Senior Management Team

  12/15/2015

• HUYA Bioscience International Expands Senior Management Team

  12/10/2015

• HUYA Bioscience International Sponsors 'Best New Drug' Category At SCRIP Awards

  12/3/2015

• HUYA Bioscience International Expands Into South Korea

  12/2/2015

• HUYA Bioscience International Announces A Strategic Alliance With The Korea Drug Development Fund

  11/30/2015